-
EP4103566
European procedure
Extract from the Register of European Patents
EP About this file: EP4103566
| EP4103566 - FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 01.09.2023 Database last updated on 26.07.2024 | |
| Former | Grant of patent is intended Status updated on 22.05.2023 | ||
| Former | Request for examination was made Status updated on 18.11.2022 | ||
| Former | The international publication has been made Status updated on 17.09.2021 | ||
| Former | unknown Status updated on 24.03.2021 | Most recent event Tooltip | 01.09.2023 | (Expected) grant | published on 04.10.2023 [2023/40] | Applicant(s) | For all designated states AstraZeneca AB 151 85 Södertälje / SE | [2022/51] | Inventor(s) | 01 /
JARVIS, Rebecca, Elizabeth MedImmune Limited Milstein Building, Granta Park Cambridge Cambridgeshire CB21 6GH / GB | 02 /
BÜRLI, Roland, Werner MedImmune Limited Milstein Building, Granta Park Cambridge Cambridgeshire CB21 6GH / GB | [2022/51] | Representative(s) | Frick, Robert Lorenz Seidler Gossel Rechtsanwälte Patentanwälte Partnerschaft mbB Widenmayerstraße 23 80538 München / DE | [2022/51] | Application number, filing date | 21712145.8 | 12.03.2021 | [2022/51] | WO2021EP56393 | Priority number, date | US202062989104P | 13.03.2020 Original published format: US 202062989104 P | [2022/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021180952 | Date: | 16.09.2021 | Language: | EN | [2021/37] | Type: | A1 Application with search report | No.: | EP4103566 | Date: | 21.12.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.09.2021 takes the place of the publication of the European patent application. | [2022/51] | Type: | B1 Patent specification | No.: | EP4103566 | Date: | 04.10.2023 | Language: | EN | [2023/40] | Search report(s) | International search report - published on: | EP | 16.09.2021 | Classification | IPC: | C07D487/04, C07D471/04, C07D491/04, A61P25/08, A61P25/22, A61P29/00, A61K31/519 | [2022/51] | CPC: |
C07D471/04 (EP,IL,KR);
A61P25/08 (EP,IL);
C07D487/04 (EP,IL,KR,US);
A61K31/519 (KR);
A61K31/5377 (KR);
A61K31/541 (KR);
A61K31/553 (KR);
A61P25/00 (KR);
A61P25/22 (EP,IL);
A61P29/00 (EP,IL);
C07D491/04 (EP,IL);
C07D491/048 (KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/51] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | KONDENSIERTE PYRIMIDINVERBINDUNGEN ALS KCC2-MODULATOREN | [2022/51] | English: | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | [2022/51] | French: | COMPOSÉS DE PYRIMIDINE FUSIONNÉS EN TANT QUE MODULATEURS DE KCC2 | [2022/51] | Entry into regional phase | 12.09.2022 | National basic fee paid | 12.09.2022 | Designation fee(s) paid | 12.09.2022 | Examination fee paid | Examination procedure | 12.09.2022 | Amendment by applicant (claims and/or description) | 12.09.2022 | Examination requested [2022/51] | 12.09.2022 | Date on which the examining division has become responsible | 23.05.2023 | Communication of intention to grant the patent | 28.08.2023 | Fee for grant paid | 28.08.2023 | Fee for publishing/printing paid | 28.08.2023 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 27.03.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2008136756 (ASTRAZENECA AB [SE], et al) [A] 1,2,10,20,27* examples 31,37; claims 26,28 *; | [A]WO2015131080 (NIMBUS LAKSHMI INC [US]) [A] 1,2,10,20,27 * compound I-183, example 128 on p.271;; claims 1,4 *; | [A]WO2018217766 (WHITEHEAD INST BIOMEDICAL RES [US]) [A] 1-29 * figures *; | [A]WO2019226643 (CHILDRENS MEDICAL CT CORP [US]) [A] 1-29 * page 0097 *; | [AD] - DELPIRE E. ET AL, "Small-molecule screen identifies inhibitors of the neuronal K-Cl cotransporter KCC2", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20090331), vol. 106, no. 13, doi:10.1073/pnas.0812756106, ISSN 0027-8424, pages 5383 - 5388, XP055800994 [AD] 1-29 * figure 4 * DOI: http://dx.doi.org/10.1073/pnas.0812756106 | by applicant | - GALANOPOULOU et al., Epilepsia, (20070000), vol. 48, pages 14 - 18 | - HUBERFIELD et al., The Journal of Neuroscience, (20070000), vol. 27, pages 9866 - 9873 | - PRICE et al., Curr Top Med Chem, (20050000), vol. 5, pages 547 - 555 | - TANG et al., Translational Medicine, (20190000), vol. 11, no. 503 | - TYZIO et al., Science, vol. 343, pages 675 - 679 | - MERNER et al., Frontiers in cellular neuroscience, (20150000), vol. 9 | - BOULENGUEZ, Nature Medicine, (20100000), vol. 16, pages 302 - 307 | - FUCHS et al., Journal of Neuropathology & Experimental Neurology, (20101010), vol. 69, pages 1057 - 1070 | - HUBNER et al., Neuron, (20010000), vol. 30, pages 515 - 524 | - WOO et al., Hippocampus, (20020000), vol. 12, pages 258 - 268 | - DUY et al., Front Cell Neurosci, (20190000), vol. 13, page 515 | - ARAUJO FURTADO et al., NeuroToxicology, (20120000), vol. 33, no. 6, pages 1476 - 1490 | - MOORE et al., Proc Natl Acad Sci USA., (20181002), vol. 115, no. 40, pages 10166 - 10171 | - CORDSHAGEN et al., Journal of Biological Chemistry, (20180000), vol. 293, pages 16984 - 16993 | - DELPIRE et al., Proc Natl Acad Sci USA., (20090331), vol. 106, no. 13, pages 5383 - 5388 | - ZHANG et al., Journal of Biomolecular Screening, (20100000), vol. 15, no. 2, page 2010 | - "Uniprot", Pharmaceutical Press, Database accession no. Q9H2X9 |